Accelerate Diagnostics Inc  

(Public, NASDAQ:AXDX)   Watch this stock  
Find more results for NYSEAMEX:AXK
19.14
-0.38 (-1.95%)
Jul 29 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 19.01 - 19.55
52 week 6.86 - 31.86
Open 19.54
Vol / Avg. 0.00/340,049.00
Mkt cap 853.32M
P/E     -
Div/yield     -
EPS -0.44
Shares 44.58M
Beta 0.74
Inst. own 20%

Key stats and ratios

Q1 (Mar '14) 2013
Net profit margin -37157.14% -31645.93%
Operating margin -41050.00% -31706.05%
EBITD margin - -30931.89%
Return on average assets -49.18% -53.86%
Return on average equity -51.95% -57.04%
Employees 47 -
CDP Score - -

Address

SUITE 108, 303 E 17TH AVE
DENVER, CO 80203
United States - Map
+1-303-8638088 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Accelerate Diagnostics, Inc., formerly Accelr8 Technology Corporation, is focused on developing and commercializing instrumentation for the rapid identification and antibiotic susceptibility testing of infectious pathogens. The Company focuses on the development of a rapid diagnostic platform, the BACcel system, intended for rapid diagnosis in life-threatening bacterial infections. The BACcel system applies its technology to eliminate bacterial culturing, thus eliminating the source of delay with testing methods. The Company�s BACcel system uses bacteriological testing principles, but applies the Company's technology to adapt them to analyze live bacteria extracted directly from a patient specimen. The instrumentation uses automated digital microscopy to measure the responses of extracted live bacterial cells to various test conditions.

Officers and directors

John Patience Independent Chairman of the Board
Age: 65
Bio & Compensation  - Reuters
Lawrence Mehren President, Chief Executive Officer, Director
Age: 47
Bio & Compensation  - Reuters
Steve Reichling Chief Financial Officer
Age: 35
Bio & Compensation  - Reuters
Pete Bantock Chief Commercial Officer
Age: 48
Bio & Compensation  - Reuters
Mark C. Miller Independent Director
Age: 58
Bio & Compensation  - Reuters
Jack W. Schuler Independent Director
Age: 73
Bio & Compensation  - Reuters
Matthew W. Strobeck Ph.D. Independent Director
Age: 41
Bio & Compensation  - Reuters
Frank J. M. ten Brink Independent Director
Age: 57
Bio & Compensation  - Reuters